Cavalier Investments’s Boston Scientific BSX Stock Holding History

Cavalier Investments’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$9.76M	–	92
2025 Q3	$9.76M	Buy	+1,000	New	+$104K	0.8%	24

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cavalier Investments's BSX Position: Q1 2026 in Review

Cavalier Investments sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 4,528 shares — an estimated $432K sold.

Cavalier Investments first reported a position in BSX in Q4 2018 and held it in 13 quarters. The position peaked at $15.9M in Q4 2024. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Cavalier Investments reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Cavalier Investments sold 4,528 Boston Scientific shares in Q1 2026, an estimated $432K.
Cavalier Investments first reported a position in Boston Scientific in Q4 2018 and held it in 13 quarters.
Cavalier Investments's Boston Scientific position peaked at $15.9M in Q4 2024.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Cavalier Investments's 13F filing for Q1 2026, filed 15 May 2026.